peterschreiber.media Morgan Stanley initiated coverage of 4D Molecular Therapeutics ( NASDAQ: FDMT ) with an underweight rating due to concerns that its gene therapy candidate 4D-150 may not be able to clear the high bar set for the drug class. The investment bank said.
